TABLE 4.

Bremelanotide pharmacology results following subcutaneous dosing of premenopausal women

Variable	Subcutaneous dose (mg)
	0.75	1.25	1.75
First in-clinic dose
n	95	97	92
Cmax, mean (ng/ml)	37.5	60.0	77.2
Coefficient of variation (%)	26.6	30.6	25.2
Cmax range (ng/ml)	16.5–59.7	28.9–126.0	14.7–115.0
Median Tmax (h)	0.50	0.50	0.58
(min, max)	(0.43, 1.17)	(0.00, 2.00)	(0.50, 2.08)
Second in-clinic dose
n	89	84	88
Cmax, mean (ng/ml)	37.3	60.1	77.7
Coefficient of variation (%)	29.3	34.6	27.0
Cmax range (ng/ml)	0–77.5	0–150.0	0–127.0
Median Tmax (h)	0.52	0.53	0.55
(min, max)	(0.0, 1.08)	(0.0, 2.00)	(0.50, 2.08)

C_max, maximal concentration; T_max, time of maximal concentration.